URGN vs VOR Stock Comparison
VOR currently leads URGN in this stock comparison, with AIQ scores of 66 vs 53. The clearest difference is momentum.
What is the main difference between URGN and VOR?
VOR leads the current stock comparison as Vor Biopharma Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
UroGen Pharma Ltd. vs Vor Biopharma Inc.
VOR leads
VOR leads by 13 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 4 points over 30 sessions. Wall Street currently favors URGN on target upside.
Competitive: 3 of 5 evidence groups support VOR, its lead is widening, and its current signal state is conflicted.
UroGen Pharma Ltd.
Vor Biopharma Inc.
The Algovestiq AIQ Score currently favors VOR over URGN, 66 versus 53 as of Nov 15, 2026. VOR's advantage is driven primarily by stronger momentum and risk resilience. VOR also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors URGN. 3 of 5 covered evidence groups favor VOR today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. VOR lead: Strengthening — the AIQ differential moved from 4 to 13 points over 30 sessions.
Compare UroGen Pharma Ltd. and Vor Biopharma Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare URGN and VOR against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum40 vs 72VOR +32
- Risk Resilience40 vs 46VOR +6
- Quality68 vs 69Even
3 of 5 evidence groups favor VOR. VOR’s edge is concentrated in momentum and risk resilience.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Value +2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
Largest factor move: Momentum +2
New signals
- TSI Bearish Crossover — bearish, momentum, short horizon
VOR's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — URGN and VOR both carry a full feed there.
The central trade-off
VOR (Vor Biopharma Inc.): the stronger current systematic profile, led by momentum and risk resilience.
URGN (UroGen Pharma Ltd.): the counter-case, on analyst expectations — but at materially higher volatility, 79.4% against 62.1%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
VORVOR on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
URGNURGN on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
VORVOR on the Momentum factor, by 32 points.
Lower downside
VORVOR on Risk Resilience, by 6 points.
Analyst upside
URGNURGN on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors VOR, analyst targets favor URGN. That disagreement is the most useful thing on this page.
| Measure | URGN | VOR | Note |
|---|---|---|---|
| Implied upside to target | +121.5% | +106% | URGN has more room |
| Target dispersion | +6.9% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 8 | 10 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor VOR. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | VOR | 53 vs 66 |
| Fundamentals | Even | EPS growth 89.3% vs -25%; TTM ROE 1.2% vs 63.2% |
| Valuation | Not covered | Not covered |
| Technicals | VOR | Price vs 50-day -29.2% vs -2.9%; vs 200-day -17.4% vs 10.8% |
| Risk Resilience | VOR | Risk Resilience 40 vs 46 |
| Analyst expectations | URGN | Target upside 121.5% vs 106% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of URGN and VOR and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 13 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VOR.
How the comparison changed
120 daily snapshots · May 27 – Nov 13VOR lead: Strengthening — the AIQ differential moved from 4 to 13 points over 30 sessions.
- Today
- VOR +13
- 53 vs 66
- 7 sessions ago
- VOR +6
- 57 vs 63
- 30 sessions ago
- VOR +4
- 63 vs 67
- 90 sessions ago
- URGN +1
- 70 vs 69
The lead changed hands 4 times in this window, most recently on Oct 12 when URGN moved ahead of VOR.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish / 2 neutral, conflicted
Only URGN
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold — bullish, momentum, short horizon
1 bullish / 2 bearish / 1 neutral, conflicted
Only VOR
- Beta Spike Warning — bearish, risk_regime, long horizon
- TSI Bearish Crossover — bearish, momentum, short horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.
VOR leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.8%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +0.52%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1URGN closes the Momentum gap — currently 32 points behind, the largest single contributor to VOR's edge.
- 2URGN's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
- 3VOR's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | URGN | VOR |
|---|---|---|
| Revenue growth (YoY) | 22.8% | 0% |
| EPS growth (YoY) | 89.3% | -25% |
| Gross margin | 91.4% | 0% |
| Operating margin | -12.4% | 0% |
| Return on equity (TTM) | 1.2% | 63.2% |
| Debt to equity | -1.57 | -0.02 |
Performance
VOR leads 5 of 6 windows| Metric | URGN | VOR |
|---|---|---|
| 1 week (5 sessions) | 5.8% | -2.3% |
| 1 month (20 sessions) | -24.2% | 7.7% |
| 3 months (63 sessions) | -46.7% | -15.6% |
| 6 months (126 sessions) | -9% | 32.7% |
| Year to date | 11.8% | 48.5% |
| 1 year (252 sessions) | 4.1% | 93% |
Technicals
VOR has the stronger structure| Metric | URGN | VOR |
|---|---|---|
| RSI (14) | 28.7 | 48.8 |
| ADX (14) | 45.1 | 8.9 |
| Price vs 50-day | -29.2% | -2.9% |
| Price vs 200-day | -17.4% | 10.8% |
| Volatility (1M, annualized) | 79.4% | 62.1% |
Risk
VOR is the more resilient| Metric | URGN | VOR |
|---|---|---|
| Beta | 1.33 | 1.7 |
| Sharpe ratio | 0.39 | 1.15 |
| Sortino ratio | 0.56 | 1.99 |
| Max drawdown | -50.8% | -33.4% |
| Current drawdown | -47.9% | -22.6% |
| Annualized volatility | 61.9% | 93.5% |
| Value at risk (95%) | -5.5% | -8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, URGN or VOR?
On the Algovestiq AIQ Score, VOR is the stronger of the two as of Nov 15, 2026, scoring 66 against URGN's 53. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is URGN or VOR the better buy right now?
VOR carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor VOR over URGN?
The composite weights Quality, Value, Momentum and Risk Resilience. VOR leads Momentum by 32 points; VOR leads Risk Resilience by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, URGN or VOR?
Analyst price targets imply +121.5% upside for URGN and +106% for VOR, so the Street currently favors URGN. That points the opposite way to the AIQ Score, which favors VOR. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, URGN or VOR?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, URGN or VOR?
URGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, URGN or VOR?
VOR on the Momentum factor, by 32 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, URGN or VOR?
VOR is the more resilient of the two, so the other name carries the higher downside risk. VOR on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is URGN more profitable than VOR?
VOR leads on the comparable margin measures — gross margin 91.4% vs 0%; operating margin -12.4% vs 0%; ttm roe 1.2% vs 63.2%.
Is VOR's lead over URGN getting stronger or weaker?
VOR lead: Strengthening — the AIQ differential moved from 4 to 13 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 4 times in that window, most recently on 2026-10-12, when URGN moved ahead of VOR.
What would change the URGN vs VOR verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: URGN closes the Momentum gap — currently 32 points behind, the largest single contributor to VOR's edge; URGN's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; VOR's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about URGN and VOR?
URGN: 2 bullish / 1 bearish / 2 neutral, conflicted. VOR: 1 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on URGN is Golden Cross Active (bullish, long horizon). On VOR it is Golden Cross Active (bullish, long horizon).
Compare URGN and VOR with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.